What is HC Wainwright’s Forecast for VYGR FY2024 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – HC Wainwright boosted their FY2024 earnings per share estimates for Voyager Therapeutics in a report issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.82) per share for the year, up from their prior forecast of ($0.97). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.31) EPS, FY2026 earnings at ($1.38) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($1.69) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the prior year, the company posted ($0.59) earnings per share.

VYGR has been the topic of a number of other research reports. Leerink Partners started coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Wedbush decreased their target price on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Finally, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $17.00.

Voyager Therapeutics Stock Performance

VYGR opened at $5.39 on Monday. The business’s 50-day simple moving average is $6.62 and its 200 day simple moving average is $7.49. The firm has a market capitalization of $294.18 million, a PE ratio of 7.59 and a beta of 0.89. Voyager Therapeutics has a 52-week low of $5.38 and a 52-week high of $11.72.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. lifted its stake in Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after purchasing an additional 1,300 shares during the last quarter. Plato Investment Management Ltd bought a new stake in Voyager Therapeutics during the first quarter worth $38,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after acquiring an additional 4,098 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Voyager Therapeutics in the 3rd quarter valued at $74,000. Finally, SG Americas Securities LLC bought a new position in shares of Voyager Therapeutics in the 2nd quarter valued at $85,000. 48.03% of the stock is currently owned by institutional investors.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. This represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.53% of the stock is currently owned by corporate insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.